Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
Keenova Therapeutics plc reports company news around its branded therapeutics portfolio for rare and unaddressed conditions. Recurring updates cover financial results, clinical publications, disease-awareness campaigns, and presentations involving products and programs such as Acthar Gel, XIAFLEX, TERLIVAZ, and collagenase clostridium histolyticum research.
The company's communications emphasize specialty therapeutic areas that include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. News also covers integration activity following its business combination, U.S. manufacturing operations, and portfolio performance drivers across established branded medicines.
Keenova Therapeutics (MNK) announced new final updated data from a dedicated ventral curvature analysis of Peyronie's disease treated with XIAFLEX (collagenase clostridium histolyticum). Results to be presented at the American Urological Association 2026 meeting indicate clinical effectiveness and safety in ventral curvature consistent with other Peyronie's disease presentations.
Keenova Therapeutics (MNK) reported first-quarter 2026 net sales from continuing operations of $468 million, driven by Acthar Gel net sales of $170 million (up 47% YoY) and XIAFLEX net sales of $134 million.
The company posted a loss from continuing operations of $114 million, reflecting non-cash fair value adjustments and Endo-related costs, while adjusted EBITDA reached $174 million. Keenova realized $23 million of merger synergies, remains on track for $100 million in 2026, and reaffirmed 2026 net sales guidance of $1.94–$2.00 billion and adjusted EBITDA of $730–$760 million. XIAFLEX clinical milestones and an NYSE listing pursuit in H2 2026 also remain on track.
Keenova Therapeutics (NASDAQ:MNK) on May 4, 2026 launched a national consumer and disease awareness campaign, Don't Be a Viking, focused on Dupuytren's contracture.
The campaign features 30- and 15-second TV spots, streaming and digital placements, and directs people to FindaHandSpecialist.com to connect with hand specialists and learn about nonsurgical treatment options.
Keenova (NASDAQ:MNK) will present new clinical analysis of TERLIVAZ® (terlipressin) at Digestive Disease Week, May 2-5, 2026. The presentation reports preliminary real-world treatment patterns and outcomes for hepatorenal syndrome-acute kidney injury (HRS-AKI) from seven U.S. hospitals and aims to inform clinical practice.
Keenova Therapeutics (NASDAQ:MNK) will report its first quarter 2026 financial results on May 12, 2026 before market open and will host a conference call the same day.
The live call is scheduled for 8:00 a.m. ET, with an audio webcast accessible via the Investor Relations site and a replay available after the event.
Keenova (NYSE:MNK) reported robust Q4 2025 results with net sales from continuing operations of $543.0M, driven by Acthar Gel $205.6M (+48%) and XIAFLEX $156.5M. Adjusted EBITDA from continuing operations was $210M–$220M and loss from continuing operations was $(105.0M)–(115.0M).
The company provided 2026 guidance of $1.94B–$2.00B net sales and $730M–$760M Adjusted EBITDA, and expects ~ $100M pre-tax merger synergies in 2026 toward a $150M run-rate.
Keenova Therapeutics (NYSE:MNK) will present new clinical analysis of TERLIVAZ (terlipressin) at the Society of Hospital Medicine Converge, March 29–April 1, 2026.
The presentation reports real-world utilization patterns and outcomes in hospitalized U.S. adults with hepatorenal syndrome‑acute kidney injury (HRS‑AKI). According to the company, TERLIVAZ is the first and only FDA‑approved therapy to improve kidney function in adults with HRS‑AKI. The study is a retrospective cohort authored by A. Sidney Barritt IV and colleagues.
Keenova (MNK) announced first-time publication of a Phase 4 retrospective analysis of XIAFLEX® (collagenase clostridium histolyticum) for recurrent Dupuytren contracture after surgery.
The multicenter review covered patients treated between January 2010 and August 2020 across 10 U.S. clinical centers, measured joint contracture changes within 12 months, and found adverse events consistent with prior CCH reports.
Keenova (NASDAQ:MNK) presented previously unpublished Phase 2 extension data on collagenase clostridium histolyticum (CCH) for plantar fibromatosis at the ACFAS Annual Meeting Feb 24–27, 2026. Findings suggest a safety profile consistent with earlier Phase 2 results and support potential long‑term safety, efficacy, and durability.
Keenova is conducting a pivotal Phase 3 trial for CCH in plantar fibromatosis, with topline results expected mid‑2026.
Keenova (NASDAQ:MNK) announced a peer‑reviewed manuscript in Journal of Foot and Ankle Surgery reporting real‑world treatment patterns for plantar fibromatosis and highlighted persistent symptoms after conservative care. The company said it is actively evaluating collagenase clostridium histolyticum (CCH) in a Phase 3 trial currently underway (Feb 16, 2026).
The study notes no FDA‑approved nonsurgical options and calls for more research on long‑term outcomes and effective therapies.